Literature DB >> 6294275

Botulinum neurotoxin type E: studies on mechanism of action and on structure-activity relationships.

L L Simpson, B R Dasgupta.   

Abstract

Single chain type E botulinum neurotoxin was isolated from culture fluids of Clostridium botulinum (strain Alaska E-43). The neurotoxin, which migrated as a single band in polyacrylamide gel electrophoresis with sodium dodecylsulfate, had a molecular weight of approximately 147,000. Single chain type E neurotoxin that was exposed to trypsin was converted to a dichain molecule. Pretreatment of the single chain molecule with 1,2-cyclohexanedione, a reagent that selectively modifies arginine residues, inhibited trypsin-induced generation of the dichain molecule. In dose-response experiments (10(-13) to 10(-9) M) on the isolated neuromuscular junction (phrenic nerve-hemidiaphragm preparation), the dichain neurotoxin was approximately two orders of magnitude more potent than the single chain neurotoxin. Neither specie of neurotoxin (1 pmol/mouse, in vivo; 1 X 10(-11) M, in vitro) was very effective in blocking autonomic transmission (vagus nerve-atrium preparation). The neuromuscular blocking action of the dichain molecule was divided into a sequence of three steps. There was an initial binding step that was relatively rapid, little influenced by temperature and which left the neurotoxin partially accessible to the neutralizing effects of antitoxin. There was a translocation step that was temperature dependent, antagonized by ammonium chloride and methylamine hydrochloride and which caused the neurotoxin to become inaccessible to the neutralizing effects of antitoxin. Finally, there was an intracellular lytic step, during which the toxin blocked excitation-secretion coupling.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6294275

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Synaptic vesicle movements monitored by fluorescence recovery after photobleaching in nerve terminals stained with FM1-43.

Authors:  A W Henkel; L L Simpson; R M Ridge; W J Betz
Journal:  J Neurosci       Date:  1996-06-15       Impact factor: 6.167

2.  Optimization of peptide substrates for botulinum neurotoxin E improves detection sensitivity in the Endopep-MS assay.

Authors:  Dongxia Wang; Joan Krilich; Jakub Baudys; John R Barr; Suzanne R Kalb
Journal:  Anal Biochem       Date:  2014-09-16       Impact factor: 3.365

3.  Expression of botulinum toxin binding sites in Xenopus oocytes.

Authors:  N M Bakry; Y Kamata; L L Simpson
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

4.  Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A.

Authors:  Virginia Roxas-Duncan; Istvan Enyedy; Vicki A Montgomery; Vanessa S Eccard; Marco A Carrington; Huiguo Lai; Nizamettin Gul; David C H Yang; Leonard A Smith
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

5.  Botulinum neurotoxins B and E translocate at different rates and exhibit divergent responses to GT1b and low pH.

Authors:  Shihu Sun; William H Tepp; Eric A Johnson; Edwin R Chapman
Journal:  Biochemistry       Date:  2012-07-02       Impact factor: 3.162

6.  The use of botulinum toxin for the treatment of overactive bladder syndrome.

Authors:  Bogdan Orasanu; Sangeeta T Mahajan
Journal:  Indian J Urol       Date:  2013-01

7.  Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody.

Authors:  Yağmur Derman; Katja Selby; Sebastian Miethe; André Frenzel; Yvonne Liu; Christine Rasetti-Escargueil; Arnaud Avril; Thibaut Pelat; Remi Urbain; Alexandre Fontayne; Philippe Thullier; Dorothea Sesardic; Miia Lindström; Michael Hust; Hannu Korkeala
Journal:  Toxins (Basel)       Date:  2016-09-12       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.